GB817385A - Process for the production of an antibiotic designated kanamycin - Google Patents
Process for the production of an antibiotic designated kanamycinInfo
- Publication number
- GB817385A GB817385A GB27640/57A GB2764057A GB817385A GB 817385 A GB817385 A GB 817385A GB 27640/57 A GB27640/57 A GB 27640/57A GB 2764057 A GB2764057 A GB 2764057A GB 817385 A GB817385 A GB 817385A
- Authority
- GB
- United Kingdom
- Prior art keywords
- kanamycin
- aqueous
- sulphate
- per cent
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22F—CHANGING THE PHYSICAL STRUCTURE OF NON-FERROUS METALS AND NON-FERROUS ALLOYS
- C22F1/00—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
- C22F1/04—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of aluminium or alloys based thereon
- C22F1/05—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of aluminium or alloys based thereon of alloys of the Al-Si-Mg type, i.e. containing silicon and magnesium in approximately equal proportions
Landscapes
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Thermal Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Mechanical Engineering (AREA)
- Metallurgy (AREA)
- Organic Chemistry (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
<PICT:0817385/IV (b)/1> A new antibiotic, kanamycin, is produced by the aerobic cultivation of a kanamycin-producing strain of Streptomyces kanamyceticus nov. spec. e.g. S. kanamyceticus NTCC 12853, in an aqueous nutrient medium containing a source of carbon, nitrogen and inorganic salts. Specified carbon sources are starch, dextrin, maltose, glucose, sucrose, lactose and glycerol. Specified nitrogen sources are nitrates, soybean meal, cottonseed meal, peanut meal, meat extract, peptone, corn steep liquor and yeast extract. Inorganic salts are magnesium sulphate, manganese chloride, zinc sulphate, sodium chloride, potassium chloride, potassium monohydrogen phosphate and calcium carbonate. A preferred medium contains starch, glucose, soybean meal, sodium chloride, potassium chloride, magnesium sulphate, potassium monohydrogen phosphate, calcium carbonate, sodium nitrate, manganese sulphate and zinc sulphate. The initial pH of the medium is 7.0, the temperature of cultivation 25 to 35 and especially 27 DEG to 32 DEG C. and the duration of fermentation 2 to 7 and especially 3 to 5 days. Karamycin is isolated from the broth by (a) solvent extraction, or (b) adsorption. In the case of (a) the (whole or clarified) broth is extracted with butanol in the presence of lauric acid or stearic acid at pH 6-8 and then with an aqueous medium at pH 2 to 4. An extraction with butanol, ethyl acetate, butyl acetate or benzene may be made to remove impurities. Alternatively, the broth is concentrated, acidified and extracted with water, methanol, ethanol or acetone. Adsorption (b) may be on (1) activated carbon at neutral or alkaline pH, followed by elution with dry or aqueous alcohol such as methanol or acidified aqueous acetone of pH 2.0; (2) a cation exchange resin preferably of the carboxylic acid type, e.g. Amberlite IRC-50 (Registered Trade Mark) at pH 6.0 to 9.0, followed by elution with aqueous hydrochloric acid, aqueous sulphuric acid, aqueous acidified organic solvents such as acetone or aqueous ammonia. The eluate is concentrated and a non-solvent added to precipitate kanamycin or its salt. After initial isolation crude kanamycin may be further purified by column chromatography using alumina (treated with sulphuric acid) or active carbon. Kanamycin is effective against Gram-positive and Gram-negative bacteria and mycobacteria: it is a basic compound forming salts with acids and containing 43.17 per cent carbon, 6.95 per cent hydrogen, 9.82 per cent nitrogen and 40.06 per cent oxygen (by difference); it is soluble in water and substantially insoluble in n-butanol, ethyl acetate, butyl acetate, ether, chloroform and benzene; Rf value in 0.2 per cent p-toluene sulphonic acid-butanol saturated with water is 0.21 to 0.26; [a ]1D = 112 DEG (C = 1 per cent water); exhibits no absorption in the ultra-violet from 220 to 400 mm ; in infra-red kanamycin sulphate shows characteristic absorption bands at the following wavelengths expressed in microns 2.85, 3.03, 3.20, 3.30, 3.43, 3.63, 3.70, 3.83, 4.70, 6.05, 6.17, 6.27, 6.60, 6.90, 7.15, 7.35, 7.52, 7.60, 7.95, 8.18, 8.76, 8.95, 9.08, 9.40, 9.70, 10.20, 10.48, 10.75, 11.13, 11.50, 11.90, 12.35, 12.80 and 13.15. The antibiotic is distinguished from neomycin B and C and neamine. Kanamycin produces an N-acetyl derivative. Kanamycin may be recovered from the fermentation broth as the hydrochloride or sulphate, which may be converted to the reineckate by treatment with ammonium reineckate. The free base may be recovered from an aqueous solution of kanamycin sulphate by adding barium hydroxide to remove the sulphate ion. Kanamycin may be used medicinally alone or in admixture with other drugs (see Group VI).ALSO:A therapeutic preparation comprises the antibiotic kanamycin (see Group IV (b)) and a pharmaceutical carrier. Optional drugs which may be incorporated in the composition are antihistamines, sulpha drugs, stimulants, local anesthetics, analgesics, laxatives, sedatives, vitamins, hormones, antifungal agents and antibiotics such as streptomycin, tetracyclines and penicillin.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP817385X | 1956-09-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB817385A true GB817385A (en) | 1959-07-29 |
Family
ID=13754759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB27640/57A Expired GB817385A (en) | 1956-09-05 | 1957-09-02 | Process for the production of an antibiotic designated kanamycin |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB817385A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110201054A1 (en) * | 2009-02-18 | 2011-08-18 | Viridis Biopharma Pvt Ltd | Process for improved recovery of fermentation products from intracellular and extracellular presence |
-
1957
- 1957-09-02 GB GB27640/57A patent/GB817385A/en not_active Expired
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110201054A1 (en) * | 2009-02-18 | 2011-08-18 | Viridis Biopharma Pvt Ltd | Process for improved recovery of fermentation products from intracellular and extracellular presence |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IE36434B1 (en) | Gentamicin antibiotics | |
GB715362A (en) | Improvements in or relating to antimicrobial agent | |
US2931798A (en) | Kanamycin and processes for the preparation thereof | |
Nakamura et al. | Isolation and characterization of bottromycins A and B | |
GB1339032A (en) | Rabelomycin and processes for its production | |
GB817385A (en) | Process for the production of an antibiotic designated kanamycin | |
GB1094566A (en) | Kasugamycin and processes for the preparation thereof | |
GB1355734A (en) | Process for producing antibiotic material | |
GB1038242A (en) | Bleomycin and processes for preparation thereof | |
Zbinovsky et al. | Isolation and characterization of antibiotic LL-AC541 | |
GB901830A (en) | A new antibiotic danubomycin and a process for its manufacture | |
GB862685A (en) | New antibiotic designated pa 155a | |
GB901273A (en) | The new organic compound tylosin, its hydrolysis product desmycosin and methods for preparing same | |
GB1292010A (en) | A new antibiotic, its production and its use | |
GB1116280A (en) | Antibiotic a28829 | |
GB729208A (en) | Improvements in or relating to a new antibiotic p.a. 95 and the preparation thereof | |
GB768971A (en) | Antibiotic d-52, its salts and method of preparation | |
GB829327A (en) | Novel antibiotic designated marcomycin and process of making same | |
IL31223A (en) | Antibiotic substance sf-733 and process for its production | |
GB1212741A (en) | A method for producing an antibiotic b-2847 | |
GB783486A (en) | A new antibiotic filipin | |
GB1356723A (en) | Antibiotic sf-1293 substance and its production and uses | |
GB757089A (en) | Improvements in or relating to antibiotics | |
GB708686A (en) | Antibiotic d-13 and its production | |
GB974562A (en) | The antibiotic a22765 and salts thereof |